Stephan Grupp MD PhD
8 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia (NCT07464951) | Stephan Grupp MD PhD | 2026-05-14 |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases (NCT05029336) | Stephan Grupp MD PhD | 2026-03-01 |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma (NCT07007117) | Stephan Grupp MD PhD | 2025-06-20 |
| Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma (NCT06934382) | Stephan Grupp MD PhD | 2025-04-29 |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma (NCT05650749) | Stephan Grupp MD PhD | 2023-05-23 |
| Co-administration of CART22-65s and huCART19 for B-ALL (NCT05674175) | Stephan Grupp MD PhD | 2023-01-25 |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) (NCT05480449) | Stephan Grupp MD PhD | 2022-09-20 |
| Orphan Indications for CD19 Redirected Autologous T Cells (NCT04276870) | Stephan Grupp MD PhD | 2020-03-12 |
Track Stephan Grupp MD PhD automatically
Every clearance here is in the API, with alerts when new ones post.